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Abstract
Background: Subtypes are widely found in cancer. They are characterized with different behaviors in clinical and
molecular profiles, such as survival rates, gene signature and copy number aberrations (CNAs). While cancer is generally
believed to have been caused by genetic aberrations, the number of such events is tremendous in the cancer tissue
and only a small subset of them may be tumorigenic. On the other hand, gene expression signature of a subtype
represents residuals of the subtype-specific cancer mechanisms. Using high-throughput data to link these factors to
define subtype boundaries and identify subtype-specific drivers, is a promising yet largely unexplored topic.
Results: We report a systematic method to automate the identification of cancer subtypes and candidate drivers.
Specifically, we propose an iterative algorithm that alternates between gene expression clustering and gene
signature selection. We applied the method to datasets of the pediatric cerebellar tumor medulloblastoma (MB).
The subtyping algorithm consistently converges on multiple datasets of medulloblastoma, and the converged
signatures and copy number landscapes are also found to be highly reproducible across the datasets. Based on the
identified subtypes, we developed a PCA-based approach for subtype-specific identification of cancer drivers. The
top-ranked driver candidates are found to be enriched with known pathways in certain subtypes of MB. This might
reveal new understandings for these subtypes.
This article is an extended abstract of our ICCABS ‘12 paper (Chen et al. 2012), with revised methods in iterative subtyping,
the use of canonical correlation analysis for driver-identification, and an extra dataset (Northcott90 dataset) for cross-
validations. Discussions of the algorithm performance and of the slightly different gene lists identified are also added.
Conclusions: Our study indicates that subtype-signature defines the subtype boundaries, characterizes the
subtype-specific processes and can be used to prioritize signature-related drivers.
Background
Cancer is initiated and driven by aberrant genetic events,
such as copy number aberrations (CNAs), called the dri-
vers of cancer. Further, quite a few cancer, such as breast
cancer [1], glioblastoma [2] and medulloblastoma [3], are
confirmed to contain subtypes, with distinct inter-subtype
molecular profiles and clinical outcomes. Different sub-
types may have arisen because of different mechanisms,
such as hits on different pathways and/or different cells-
of-origin [4] within the same tissue/organ. Stratifying the
patients into appropriate subtypes is the key to uncover
the drivers of these mechanisms. This step, referred to as
the subtyping of cancer, usually relies on the class discov-
ery of cancer expression datasets.
There is a large body of techniques available for class dis-
covery within a cancer dataset, such as spectral clustering
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[5], non-negative matrix factorization [6], etc. A straight-
forward and one-step strategy is to employ one such tech-
nique to train the class labels for a group of samples, and
detect the set of most differentially expressed genes (DEGs)
using the trained labels and the same expression data. The
set of DEGs, called the gene signature, can be used for
functional analysis of the corresponding subtype.
On the other hand, genetic aberrations enriched in a
cancer subtype may also be related to, or even have causal
roles in the corresponding subtype. Particularly, one type
of genetic events, CNA, is widely found in the cancer gen-
omes [7]. CNAs are also found to be positively correlated
with the raw expressions of affected genes [3]. In some
cancer, such as medulloblastoma, the CNA patterns are
also found to be subtype-dependent [8]. However, given
the large number of CNA-affected genes that often occur
within a cancer genome, it is not practical to assume that
all of them are tumorigenic. Instead, most of the CNAs
may just cause mechanic responses in the affected genes’
expressions, but otherwise are not related to the cancer
process. Apart from these, a small proportion of CNAs
may be involved in the initiating, driving or sustaining of
the cancer process, which also gives rise to the subtype-
specific signature. This is summarized in the hypothetical
diagram in Figure 1. The diagram indicates that the gene
signature not only reflects the underlying processes char-
acterizing individual subtypes and hence can be used
for subtyping; but may also be used to trace the subtype-
specific drivers.
In recent years, tools such as GISTIC [9] have gained
increasing popularity for their capabilities to discover
recurrent CNA patterns of a clinical condition. Genes
within these recurrent patterns are assumed to be patholo-
gically and clinically important. Unfortunately, in the
highly twisted cancer genomes, recurrent regions tend to
occupy broad regions and harbor hundreds of genes or
more, making it less specific to equate these genes to can-
cer drivers. A recent study [10] attempts to relate recur-
rent CNAs with co-expression modules, in an effort to
find melanoma drivers, in a subtype-non-specific manner.
Here, we focus on the subtype-signature and within-
subtype recurrent CNAs; and propose an integrative
approach to perform subtyping and driver-identification.
The approach consists of two stages. First, given a cancer
expression dataset, perform subtyping to train class labels
for individual cases and detect signature genes for each
subtype (i.e., class). Second, CNA measurements (e.g.,
SNP arrays) corresponding to samples of each subtype
are subjected to pre-selection procedures, e.g. GISTIC,
for a reduced set of driver candidates. The driver candi-
dates are then ranked in order of correlation with the
corresponding subtype’s signature genes. The top ranked
candidates will be manually reviewed for their potential
roles in the subtypes. The approach is summarized in
Figure 2. The following describes key issues regarding the
algorithmic design for these two stages at the concept
level, with further details in Methods.
Iterative subtyping
The one-step approach described above is both easy to
implement and computationally efficient. However, it may
suffer from overfitting, as the determination of the number
of clusters given a clustering dendrogram can be quite arbi-
trary. This is because the relation between the class labels
and the signature genes is not considered. Suppose there
are K inherent subtypes, each with a set of signature genes,
the large number of non-signature genes, together with
measurement noises, may blur the subtype boundaries.
This results in multiple ways of cutting a dendrogram, as
in the case of medulloblastoma where various numbers of
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Figure 1 A hypothetical diagram depicting the role of CNAs in cancer, subtypes and their relations with signatures. While most CNAs are
assumed to affect the expressions of the affected genes only and have limited harms, a few CNAs together with other drivers, e.g. mutations, may
perturb subtype-specific pathways and trigger subtypes of cancer. This consequently leads to the observation of a set of signature genes.
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clusters have been reported [3,11]. As a result, different
DEGs will be produced by different methods on the same
disease. Yet as depicted in Figure 1, the real pathway-
related DEGs (i.e., signature) should be inherent in each
subtype but not dependent on how the dendrogram is cut.
To address this issue, we first introduce a regularization
by defining a subtype as the smallest group of samples
that share a substantial set of DEGs (against all other sam-
ples, including normal cases). This is to ensure that on the
one hand, as many subtypes are uncovered as possible,
while on the other hand, each of them is characterized
with a sufficient number of signature genes. In practice,
this can be implemented by starting with a large number
and cutting the resulting dendrogram into corresponding
number of clusters. The subtype-signature detection
(described in Methods) is applied to the resulting clusters.
The resulting clusters can be categorized into good clusters
and bad clusters. The former has a sufficiently large num-
ber of signature genes, while the latter has fewer than a
certain percentage of total signature genes. Cases of the
bad clusters are re-assigned to their closest good clusters.
Further, since the inherent signature genes determine the
class boundary more than non-signature genes, the union
of the signature genes after one iteration may be used as
input to inform the subset of genes on which clustering is
to be performed, in the next iteration.
The next iteration will attempt to cut the dendrogram
into the same number of clusters as the good clusters in
last iteration. This is based on the assumption that each
step of clustering and signature detection produces a set
of signature genes that is getting closer to the genuine sig-
natures. The above procedure ensures that the number of
clusters to be tested is monotonously decreasing. To avoid
K being trapped in small numbers, at each iteration, the
number of clusters to be tested is increased by a small
margin ΔK above the number good clusters in the last
step. In this way, this algorithm is made to favor a larger
number of patterns over smaller ones, if both have suffi-
cient numbers of signatures genes.
The above procedure is iterated until the algorithm con-
verges, indicating that the optimum where maximum
number of subtypes each with a sizable signature has been
reached. Our iterative approach can be compared to the
iterative algorithm for a bounded (and regularized) optimi-
zation problem. In cutting the dendrograms, resulting
clusters that contain only one case are considered unlikely
to be a subtype and are re-assigned to other core clusters
(i.e., containing more than one case). The procedural
implementation of the algorithm is given below.
Given an expression dataset E ∈ RN×M with N samples
and M genes, select an initial set of genes, say the top 10%
of genes with largest variances, to yield a reduced dataset
Eˆ. Start with a (sufficiently) large number K, the algorithm
consists of the following steps:
1. Perform clustering (e.g., spectral clustering) on Eˆ,
and form a dendrogram.
2. Cut the dendrogram into K clusters. If this results
in some clusters with one sample, assign these samples
to their closest clusters. Consequently, we obtain K′
core clusters (K′ ≤ K).
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Figure 2 Approach overview. Gene expression microarray measurements are used for training the class labels and detecting signature genes.
The copy number profiles (by SNP arrays) of the corresponding samples undergo candidate pre-selection by GISTIC. A subtype-specific method
identifies top signature-related candidates.
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3. Detect the signature (described in Methods) Sk for
each subtype k Î {1, .., K′}, using the original dataset E.
4. Obtain the union of signatures: F = S1 ∪ … ∪ SK′.
5. For clusters (i.e., bad clusters) whose signature genes
are fewer than a percentage of |F|, the cases in these clus-
ters are re-assigned to their closest good clusters. This
results in a total number of clusters K″ ≤ K′.
6. Replace the above Eˆ with one that is based on the
set F.
7. Update K = K″ + ΔK, where ΔK is a small positive
integer.
8. Repeat Steps 1 to 7, till a certain convergence criter-
ion is reached, e.g. the number of subtypes remains
unchanged.
The subtype-specific driver identification
According to Figure 1, even within a subtype, there could
be different driving events. Here, we focus on the dominant
subtype-specific events, i.e., CNAs. A CNA-affected gene
can activate the cancer process through its CNA-induced
aberrant expressions. Therefore, its expression may be cor-
related with the signature genes, which are believed to be
the consequences of subtype-specific processes. This pro-
blem is equivalent to finding variables in one set that maxi-
mally correlate with another set of variables, a problem
known as canonical correlation analysis (CCA) [12]. Parti-
cularly, given a subtype k and its signature Sk(|Sk| = J) and
L pre-selected candidate CNA genes, two vectors of vari-
ables xa ∈ RJ×1 and xb ∈ RL×1are used to denote the
expressions of them, respectively. The objective is find two
vectors wa ∈ RJ×1 and wb ∈ RL×1, such that:
ρ =
wTaCabwb√
wTaCaawaw
T
b Cbbwb
(1)
is maximized, where Cab is the between-set covariance
matrix and Caa and Cbb are the within-set covariance
matrices. The pre-selected candidates whose absolute
weightings |wlb|(l = 1, ..., L) are largest are assumed to be
related with the signature genes, whereas those whose
weightings are close to zero as assumed to be not related.
Similarly, signature genes whose absolute weightings are
large can be assumed to be related with the candidates. If
thresholds are chosen, solutions to the above problem
result in a CNA-regulated network consisting of subsets of
signature genes and pre-selected candidates.
In solving Eq. (1), techniques such as sparse canonical
correlation analysis (SCCA) [13] kernelize the covar-
iance matrices, and reduce the problem to:
maximize
wa,wb
wTaCabwb + μ|wa| + μ|wb| (2)
subject to wTaCaawa = w
T
aCbbwb = 1.. This avoids the
hard thresholds above, but the solution is highly sensitive
to the hyperparameter µ. Note that the magnitudes of wa
and wb do not matter, e.g., if wTaCaawa = 1, one can
replace wa with w˜a = wa/
√
wTaCaawa. The key becomes
finding the directions of wa and wb such wTaCabwb is max-
imized. This is similar to the idea of principal component
analysis (PCA). Specifically, we may assume that a
row-wise zero-mean operation has been applied to Cab.
A PCA approach can next be applied to determine the
correlation of each CNA with the set Sk, as follows:
a. Perform an SVD : Cab = UVT, and then project Cab
onto the first principal component u1 of U, to give
wˆb = CTabu1. The individual entry of wˆb represents the
overall correlation of each CNA gene with the set of sig-
nature genes.
b. For a candidate CNA gene l Î {1, .., L}, the more posi-
tive wˆlb the more gene l is positively correlated with Sk, and
vice versa. Therefore, the values of wˆb serve as indicators
of driver potential for the candidate CNA genes. For con-
venience, wˆlb referred to as the driver potential of a
candidate.
c. The p-values of wˆb can be obtained by generating a
random set of signature genes and repeating the above
procedure to produce a null distribution for wˆb. The can-
didate drivers can then be ranked by their p-values.
In the above, if we let wˆa = u1, then wˆTaCabwˆb = uT1CabCTabu1 = σ 21 ,
where s1 is largest singular value of Cab. Note that the
above procedure may not lead to the maximum value for r
in Eq. (1), but as shall be shown in the Results, it effectively
detects signature-related candidates.
Results and discussion
To implement the proposed approach, we applied it to
medulloblastoma (MB) datasets. MB is a pediatric brain
tumor that usually affects children below the age of 15.
The overall five-year survival rate for MB-affected children
is poor (around 50% [14]) and varies a lot from patient
to patient, subject to different predisposition conditions.
Integrative genomic studies [3,8] in recent years have
attempted to classify MB patients into various numbers of
subtypes, two of which are well-accepted, namely, the
Wnt- and Shh-pathway associating subtypes, respectively.
For the remaining non-Wnt/non-Shh patients, there are
still debates on the exact number of subtypes inside this
group.
Dataset-independent convergence of the subtyping
algorithm
We applied the subtyping algorithm to three expression
datasets of medulloblastoma. The set of genes with top
10% variances was chosen to be the initial gene set for the
algorithm. Clusters with fewer than 1/(4K′) of all detected
signature genes were determined to be bad clusters, where
K′ is the core cluster number as defined in the algorithm
Chen et al. BMC Bioinformatics 2013, 14(Suppl 18):S1
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above, and ΔK was set to 1. The key parameter that defines
the degree of specificity of a DEG, the subtype-specific fold
change threshold (FCT) (described in Methods), was varied
from 0 to 2.0 on all three datasets (with initial cluster num-
ber fixed at 20), to assess the convergence properties of the
algorithm. As shown in Figure 3A-C, in all three datasets,
as the FCT increases, the convergence is enhanced. For
example, when FCT is 1.0 or 2.0, the algorithm efficiently
converges to three in all datasets. Whereas, when the FCT
is small, e.g., 0 (black curves), 0.25 (red curves) or 0.5
(green curves), a slight change in the FCT causes the algo-
rithm to converge to different numbers of clusters (the red
and black curves in A), or not converged at all (the red
curve in C). This suggests that the subtype-specificity
imposed on signature selection does increase the conver-
gence of the iterative algorithm.
We then fixed the FCT to be 1.0, and varied the initial
number of clusters, from 2 to 20, as shown in Figure 3D-
F. Again, the algorithm converges within several iterations
on all datasets to the same number of clusters, namely
three clusters. Figure 4 shows the numbers of cases and
signature genes in each subtype as the algorithm con-
verges, and the converged dendrograms, after 10 itera-
tions. As a comparison, the aforementioned one-step
approach using the same initial set of genes and same
clustering method (i.e., spectral clustering) was applied to
the three MB datasets and the resulting dendrograms are
shown in Figure S1 (Additional file 1). It appears that the
converged dendrograms in Figure 4 demonstrate much
clearer subtype boundaries than the corresponding
dendrograms in Figure S1.
Cross-dataset validations of identified subtypes and
characterization of them by signatures
Since the datasets all converge to three subtypes, they are
labeled as subtypes A, B and C. To test if the converged
subtypes are dataset-independent, we performed two ana-
lyses. First, the converged signatures of the datasets were
compared in a pairwise manner, as shown in Table 1.
From the table, the detected signatures are highly specific
to their corresponding subtypes and highly reproducible
on different datasets. Second, we performed cross-valida-
tions by using one dataset and its trained labels and signa-
tures to predict the labels of another dataset, and vice
versa. The datasets were normalized (described in Meth-
ods) before being used for cross-validations and the k-NN
method (k = 3) was used to predict the labels of the testing
sets. The predicted labels were compared with the testing
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Figure 3 Convergence of the iterative subtyping algorithm. A-C, The convergence properties of the subtyping algorithm on the three datasets,
Cho73 (A), Northcott90 (B) and Kool62 (C), each with various subtype-specific FCTs. D-F, The convergence properties to the three medulloblastoma
datasets as above, each with various initial numbers of clusters ranging from 2 to 20. The FCT of 1.0 is used in all experiments in D-F.
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set’s self-trained labels to form a confusion matrix, from
which the accuracy can be computed. Table 2 shows the
cross-validation results. All the cross-validations have
accuracies higher than 95%. These two analyses indicate
that the identified subtypes are highly stable and indepen-
dent of datasets.
To characterize the converged subtypes, the gene signa-
tures in the converged iterations were examined. Additional
file 1 - Table S2 shows the pathway enrichment analysis of
subtype signatures by GSEA [15]. From the table, Subtype
A is significantly enriched with Wnt-pathway genes, while
Subtype B is enriched with Shh-pathway genes. A compari-
son of the cases in Subtypes A and B with studies that pub-
lished the data (Additional file 1 - Table S1) confirms that
these two subtypes are the Wnt- and Shh-pathway associat-
ing pathways, respectively. For convenience of discussion,
these two subtypes are referred to as the WNT and SHH
subtypes, respectively. Examples of key signature genes of
Figure 4 The subtypes and signatures as the algorithm converges. The numbers of cases and signatures (in brackets) in each good (and
core) clusters as the algorithm converges (in 10 iterations) on three datasets, Cho73 (A), Northcott90 (C) and Kool62 (E). The cases are ordered
according to subtyping of the last (converged) iteration. All experiments were started with 20 initial clusters, FCT set to 1.0 and ΔK = 1. The
converged dendrograms of the corresponding datasets are shown in B, D and F, respectively.
Chen et al. BMC Bioinformatics 2013, 14(Suppl 18):S1
http://www.biomedcentral.com/1471-2105/14/S18/S1
Page 6 of 13
the subtypes (of the Kool62 dataset) are shown in Figure 5
(complete lists and plots in Additional file 2).
From Figure 5 and Additional file 2, it can be seen that
the detected signature genes are specifically up-regulated
or down-regulated in a particular subtype, and the inter-
subtype variations in the non-specific subtypes are highly
suppressed. Most importantly, these subtype-specific
DEGs are not only numerically correlated but also func-
tionally related. For example, the five genes in Figure 5A
are all involved in the Wnt-pathway. FZD10 codes for the
protein Frizzled, which is a membrane receptor for Wnt.
Its abundant expressions may lead to the activation of
Wnt pathway. LEF1 codes for a key transcription factor
of the Wnt pathway and is responsible for the transcrip-
tions of many Wnt target genes. Of interest, a number of
genes that have antagonistic roles, such as the DKKs
(Dickkopfs) and AXIN2 [16], are also up-regulated. These
genes might be the consequences of negative feedback
controls of the activated pathways. A similar phenom-
enon can be found in SHH (Figure 5B), where GLI1/2 are
the key transcription factors and are specifically up-regu-
lated, resulting in targets such as HHIP [17] and PTCH1
being highly expressed, too. HHIP in return regulates the
Shh-pathway [18], while the protein Patched encoded by
PTCH1 negatively regulates the Shh-pathway [19].
Indeed, inhibition of PTCH1 is among the recent
attempts to find drug targets for cancers including
medulloblastoma [20]. Overall, these signature genes
confirm our hypothesis that they are the consequences of
the subtype-specific cancer processes.
Table 1 Cross-dataset comparisons of converged subtype signatures.
Datasets and subtypes Northcott90 Kool62 # s.g.
A B C (# o.v.g.) A B C (# o.v.g.) (# n.s.g., %)
Cho73
A 136 0 1 207 2 6 345 (128, 37.1)
B 4 64 3 6 105 6 222 (56, 25.2)
C 0 1 37 3 5 66 110 (60, 54.5)
(# o.v.g.) (237) (378)
Northcott90
A 260 1 2 377 (97, 25.8)
B 1 110 2 175 (45, 25.7)
C 1 0 81 150 (77, 51.3)
(# o.v.g.) (451)
# s.g. 377 175 150 757 335 307
(# n.s.g.) (97) (45) (77) (219) (126) (172)
(%) (28.9) (37.6) (56.0)
The datasets have different numbers of probe-sets and were normalized separately, leading to different numbers of signature genes for different datasets of a
subtype. o.v.g.=overlapping genes; s.g.=signature genes; n.s.g.=negative signature genes.
Table 2 Cross-dataset validations of the subtypes.
Testing sets
Training sets and self-trained subtypes Cho73 Northcott90 Kool62
A B C (accu.) A B C (accu.) A B C (accu.)
Cho73 (98.9%) (96.7%)
A 7 0 0 9 0 0
B 0 27 0 0 13 0
C 0 1 55 0 2 38
Northcott90 (97.3%) (100%)
A 8 0 0 9 0 0
B 0 17 2 0 15 0
C 0 0 46 0 0 38
Kool62 (100%) (100%)
A 8 0 0 7 0 0
B 0 17 0 0 28 0
C 0 0 48 0 0 55
This table shows the numbers of cases in each testing set predicted to be of a subtype trained by the training set (first column). For example, the “2” in the
testing set Kool62 indicates that 2 cases were self-trained to be of subtype B, but predicted to be of subtype C by the Cho73 dataset. accu.=accuracy.
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The third subtype (Subtype C) has the largest number of
patients in all three datasets. Note that, this group was
further divided into various numbers of subtypes, as
shown in Additional file 1 - Table S1. Indeed, in the itera-
tive process, our algorithm also detects that there can be
four or five core clusters in the Kool62 datasets (iterations
1 to 3, Figure 4E). But gradually, core clusters containing
too few signature genes were determined to be bad clus-
ters and cases in them were re-assigned to their closest
good clusters, before the algorithm converges. To further
investigate the problem, we used our signature detection
algorithm and the labels reported by the original studies to
detect signature genes for the subtypes. As shown in Addi-
tional file 1 - Table S1, many subtypes claimed by previous
studies contain extremely low numbers of signature genes,
i.e., subtype-specific DEGs. For example, Group D in the
Northcott90 dataset contains only 6 signature genes, and
Subtype C in Kool62 contains only 5 signature genes. We
then used cases of each of the non-Wnt/non-Shh (NWS)
subtypes, with cases of the Wnt and Shh subtypes, and the
normal cases to detect signature genes (using same techni-
que as above, with FCT = 1.0) for each of the NWS sub-
types claimed by the previous studies. It turns out that
these NWS subtypes have high overlaps in signature genes
(Table 3). For example, Group C and Group D in the
Northcott90 dataset have 76 overlapping signature genes,
which is more than 40% of the signature genes in both
groups. Similarly, the NWS subtypes C, D and E in Kool62
have 46 overlapping signature genes, which is about
20~40% of the signatures of the corresponding subtypes.
Although in the Cho73, the five NWS subtypes have only
one overlapping signature gene, when only selective NWS
subtypes are considered, substantial overlaps can be seen.
For example, Subtypes 4 and 5 share 34 signature genes,
which is more than 35% in both subtypes. This further
confirms that signatures of these subtypes are highly over-
lapping, which in turn means that the NWS subtypes are
functionally overlapped with each other. Given these ana-
lyses, it is reasonable to favor the convergence results
above by referring to all NWS cases as one subtype,
namely, the NWS subtype.
Note that, the NWS seems to be more negatively regu-
lated than other subtypes, as it contains more negative sig-
nature genes than positive ones (Table 1, 51.3~56.0%),
while the WNT and SHH subtypes have far fewer percen-
tages of negative signature genes (25.2~37.6%). Indeed,
not only was the numbers of NWS subtypes not clear, the
functional characterization of them has not been as suc-
cessful as the WNT and SHH subtypes either, where
dominant pathways exist evidently. The signature genes by
Figure 5 Examples of key signature genes. Examples of gene signatures for individual subtypes in Kool62. A, B, C: example key signature
genes in Subtypes A, B and C, respectively. Within each plot, the three boxplots refer to expressions of a gene in the three subtypes,
respectively. Normal refers to normal cases. Also shown are the original data with small amount of jittering on the horizontal axis. FC: fold
change. Ranked by LIMMA adjusted p-values.
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this study may give a hint on the underlying process of
NWS. As shown in Figure 5C, a Wnt-pathway inhibitor
NLK [21] is specifically up-regulated. Also negatively regu-
lated are the Notch pathway receptor NOTCH2 and the
growth factor PDGFA. The suppression of these genes
indicates that as compared with WNT and SHH, where
the key pathways are activated, NWS may have an oppo-
site mechanism, namely, some key pathways are inacti-
vated. In all, our study confirms the hypothesis that gene
signatures define the subtype boundaries and unveil sub-
type mechanisms. Finding the correct boundaries depends
on sufficient signature genes contained in the subset of
genes used for clustering, and detecting the signatures
depends on the correct subtype boundaries. This justifies
the above iterative subtyping algorithm.
Subtype-specific copy number landscapes and candidate
driver pre-selection
Copy number profiles of the two datasets with publicly
available SNP arrays, Cho73 and Northcott90, were
inferred as described in Methods. The copy number land-
scapes are show in Additional file 1 - Figure S3. As shown
in Figure 2, profiles of each subtype are further processed
with GISTIC (http://via genepattern.broadinstitute.org) for
detection of recurrent CNAs within each subtype. Copy
number profiles with log2(ratio)-1 greater than 0.35 are
considered to be copy number gains, while those below
-0.35 are considered to be copy number losses. The sub-
type-specific GISTIC landscapes of the Cho73 dataset is
shown in Figure 6, and those for the Northcott90 dataset
is shown in Additional file 1 - Figure S4. The q-value
threshold of 0.01 is used to determine recurrent CNA
regions. Genes (UCSC human reference assembly hg18)
within these regions are considered to be CNA-affected
genes. The numbers of CNA-affected genes are tabulated
in Additional file 1 - Table S3.
As Figure S4 and Table S3 show, the copy number land-
scapes and GISTIC landscapes demonstrate extremely
strong subtype-specificity. For example, Subtype A is
dominant with Chr6 deletions, and Subtype B is character-
ized with Chr9 deletions. Subtype C is more complex,
CNAs are observed in Chr7-8, Chr11, Chr16-16, etc.
These patterns are also highly dataset-independent. The
overlapping candidates in Table S3 were taken to be the
pre-selected CNA candidates.
Testing the driver identification algorithm with synthetic
data
To test the driver identification algorithm, we generated
a synthetic gene expression dataset with 10,000 genes
and 100 cases. Entries of the dataset were initialized with
identically and independently distributed standard Gaus-
sian noises. The first 100 genes are assumed to be signa-
ture genes and the next 200 are assumed to be candidate
genes, while the remaining 9,700 genes are assumed to
be non-signature and non-candidate (NSNC) genes. Each
of the candidate genes i is given a weighting of wi. We
added synthetic inter-dependencies to the signature and
candidate genes by updating each signature gene with
x˜j =
∑
i
wicijxi + xj, where xi and xj are the initialized
Table 3 The subtype signatures of the non-Wnt/non-Shh subtypes by previous studies.
Datasets and original labels Subtype WNT (# s.g.) Subtype SHH (# s.g.) NWS subtypes (# s.g.)
Cho73
1 313 243 34 *
2 5 7 342 237 45 *, ‡, ¶
4 366 222 75 †, ‡, ¶
5 339 244 93 †, ¶
7 330 245 6
(Total overlaps) (203) (127) (1)
(Selective overlaps) Northcott90 (* 7, † 34, ‡ 25, ¶12)
Group C 330 179 170
Group D 396 181 186
(Total overlaps) (253) (112) (76)
Kool62
Subtype C 773 287 284 *,‡
Subtype D 738 299 237 *, †, ‡
Subtype E 657 268 105 †
(Total overlaps) (498) (167) (46)
(Selective overlaps) (* 158, † 66, ‡ 53)
Each row represents the numbers of signature genes for the WNT, SHH and one of the NWS subtypes (the label of which is shown on the first column of each row),
respectively. The total overlaps refer to the intersection of all signatures of a group in each dataset, e.g., |SSubtype C ∩ SSubtype D ∩ SSubtype E| = 46. Selective overlaps refer
to the intersection of the signatures with the same symbol. The difference between this table and Table S1 is that in the latter, all subtypes are trained together, while
in the former, only one of the reported NWS subtypes is trained at a time with the WNT, SHH and normal cases for detection of signatures. s.g.=signature genes.
Chen et al. BMC Bioinformatics 2013, 14(Suppl 18):S1
http://www.biomedcentral.com/1471-2105/14/S18/S1
Page 9 of 13
gene expressions of the i-th candidate and j-th signature
genes, respectively; and cij is a random number (~ U
(0, 1)) indicating the regulating potential of candidate i
on signature j. We tested the algorithm with four types of
wi, namely, wi ~ U[−1, 0], wi ~ U[0, 1], wi = 0 and wi ~ U
[−1, 1]. As additional file 1 - Figure S5 shows, when wi
are initialized with non-positive random numbers, the
estimated driver potentials wˆ′s are significantly lower
than those of the NSNC genes. Similarly, when wi are
initialized with non-negative random numbers, wˆ′s are
significantly higher than those of the NSNC genes. When
wi = 0, wˆ′s have no significant differences in the signature
or NSNC genes. And when both positive and negative
weightings are used, although no significant difference is
observed in the means, the tails of the two distributions
are very different. Particularly, the distribution of wˆ′s for
the signature genes has longer tails on both sides.
This study indicates that the technique is able to identify
the potential drivers by using the NSNC genes as the null
model, if the inter-dependencies between the drivers and
the signature still exist at the time of measurement.
Subtype related driver candidates revealed by driver
identification
The above technique was applied to the two datasets
Cho73 and Northcott90, where both expression and CNA
profiles are available. Additional file 2 - Figure S6 shows
the candidate and null distributions for the subtypes in
both datasets. The curves demonstrate similar patterns in
different datasets for the same subtype. For example, in
Subtype A (WNT), CNA candidates of both datasets tend
to have longer negative tails, while in Subtype B (SHH),
CNA candidates of both datasets tend to have longer posi-
tive tails. In Subtype C (NWS), CNA candidates of both
Figure 6 Subtype-specific GISTIC landscapes of the Cho73 dataset. The three sub-plots correspond to GISTIC copy number landscapes of
the three subtypes of the Cho73 dataset, respectively. A, Subtype A (WNT); B, Subtype B (SHH); C, Subtype C (NWS). In each subplot, the upper
panel (red) corresponds to the recurrent copy number gains, while the lower panel (blue) corresponds to the recurrent copy losses. The
numbers to left of each panel refer to the G-scores. The numbers to the right of each panel refer to the − log10 q-values. The green lines refer
to the q-value threshold of 0.25 (or − log10 q = 0.602). The numbers (1 to 22) in-between the panels refer to the autosomes.
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datasets have slightly longer tails than the null distri-
butions. Further, the significant candidates are found to
be highly reproducible (30.0%~44%, Additional file 2 -
Table S4).
Table 4 shows the reproducible top-ranked (p-value
<0.01) candidate drivers in each subtype. Of note, all
three subtypes contain some genes that seem to suggest
the underlying pathways that characterize the subtypes.
For example, Subtype A candidate drivers include
MAP3K7, which has inhibiting roles in the Wnt-pathway
[22]. Its deletion might cause the difficulty to inactivate
Wnt-pathway and results in a persistently activating
Wnt-pathway. Further, TULP4 is recently identified as a
candidate suppressor gene in the Wntassociating subtype
[23]. The top candidate driver in Subtype B, PTCH1, is a
key gene in the Shh-pathway. Its deletion may result in
the inability to inhibit Smoothened, and activate Shh
permanently. Indeed, mutations in PTCH1 have been one
of the top targets in recent literature attempting to find
predisposition loci for MB [24]. Perhaps of most interest
is the Wnt-associating genes, such as FZD1, PPP3CB and
NLK, that are found in Subtype C. As compared with
Wnt- and Shh-subtypes, the gene signature of this sub-
group of MB does not seem to be significantly enriched
with any canonical pathways. The candidate drivers that
significantly correlate with the signature genes here seem
to suggest that some Wnt-pathway activities are involved
in Subtype C; although the exact roles of Wnt have yet to
be clarified, as both NLK and FZD1 are amplified but the
former has inhibiting while the latter has promoting
roles.
Conclusions
In this work, a two-stage algorithmic framework was
developed to perform gene-signature based cancer sub-
typing and to identify subtype-specific CNA drivers. The
algorithm was applied to datasets of medulloblastoma,
producing dataset-independent subtyping results. The
driver identification results were found to be enriched
with cancer-driving pathways. This study is novel in the
following three aspects.
First, the signature-based subtyping technique ensures
that as many subtypes are uncovered as possible while
each of them is required to have a sufficient number of
signature genes. This emphasis on subtype-specificity of
signature genes allows for functional interpretation of the
cancer process or pathways underlying each subtype. This
procedure is not only a technique, but also a concept of
viewing cancer subtypes.
Second, a comparison of our results with previous results
indicates that the non- Wnt/non-Shh subtypes have high
overlaps in their gene signatures, resulting in their merger
into one single subtype (the NWS subtype) by our algo-
rithm. Although distinct clusters can be observed in the
NWS subtype, the fact that their signature genes are highly
overlapping suggests that these distinct clusters may be
due to non-functional causes, such as different copy num-
ber profiles, different cells-of-origin, etc. Therefore, it is not
appropriate to classify them as expression subtypes, and a
future direction would be to extract copy number subtypes
that explain these distinct clusters under NWS.
Third, the proposed driver identification method
relates the within-subtype recurrent genetic events to the
subtype signature based on the strengths of their inter-
dependencies. The idea to conduct this in a subtype-spe-
cific manner echoes the ultimate purpose of subtyping:
towards more refined understandings of the disease. This
idea can be further explored. For example, as depicted in
Figure 1, most of the CNAs may be passengers, and some
CNA drivers may have hit-and-run properties, i.e., inter-
dependencies do not hold by the time of measurements
(as a result of dynamic processes). This makes them
non-observable by the current method. Further, other
types of candidate drivers, such point mutations and
DNA-methylation, may be screened as well.
Methods
Datasets and preprocessing
Three publicly available medulloblastoma datasets were
used.
The first dataset consists of 73 primary MB samples and
11 normal cerebellum controls by Cho et al. [8] (GEO:
GSE19399). All cases in this dataset except the controls
have matched SNP arrays.
The second dataset consists of 90 primary MB cases
in both expression (exon) arrays and SNP arrays by
Table 4 Candidate CNA drivers within each subtype.
Subtypes Significant candidate drivers
Subtype A
(WNT) NRN1, SOX4, NUP153, FAM8A1, C6orf62, MRS2, BTN2A1, ZNF193, ZNF187, BAT3, C6orf134, ZNF318, UBR2, KIAA0240, CDC5L, MUT, ICK, FBXO9,
PTP4A1, SMAP1, SLC35A1, RNGTT, SNAP91, MAP3K7, IBTK, SFRS18, ZNF292, PHIP, DOPEY1, SYNCRIP, CASP8AP2, MARCKS, HDAC2, ASF1A,
FOXO3, HSF2, CDC2L6, TSPYL4, MED23, TRMT11, FAM184A, CCDC28A, HECA, AHI1, RBM16, TULP4, TCP1, TBP
Subtype B
(SHH) PTCH1, SLC35D2, ANGPTL2, TRPM3, UGCG, ALAD, HDHD3, STOM, ASTN2, RABGAP1, GOLGA1, AK1, SPTAN1, DNM1, BAT2L, NPLOC4
Subtype C
(NWS) PDGFA, SRI, PCOLCE, EPHB4, TRIP6, SYPL1, MDFIC, MAP2K6, GPRC5C, NAV2, AHNAK, GNG3, GPR56, MAF, PMP22, IQCE, CHN2, POM121,
GTF2IRD1, PCLO, FZD1, AKAP9, PSMD11, NLK, RHOT1, ACLY, MPP3, CBX1, MMD, HEATR6, MED13, KCNJ2, TEX2, PPP3CB, DLG5, CHD3
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Northcott et al. [25] (GEO: GSE21166 and GSE14437).
Four cerebellar samples from (GEO: GSE13344) were
used as controls for this dataset.
The third dataset consists of 62 primary MB samples
from Kool et al. [3] (GEO: GSE10327). No publicly avail-
able CNA measurements are available for this dataset.
Another nine cases of expression profiles of cerebellum
were obtained from the controls of a schizophrenia study
(GEO: GSE4036). These nine cases are in the same plat-
form as the Kool dataset and were used as the controls for
current study.
For convenience, the three datasets are referred to as
Cho73, Northcott90 and Kool62, respectively.
Expression arrays of all cases in all three datasets were
processed with the RMA algorithm [26] or its variants.
Since the three datasets are in different platforms, some
genes are measured in one but not the other datasets. To
handle this, only the set of genes common to both data-
sets are used, and their probesets are normalized, when
performing cross-dataset validations. Specifically, given a
gene with means m1 and m2, and standard deviations s1
and s2, in two cross validating datasets, respectively, the
normalized expression of this gene shall have a mean of
(m1 + m2)/2 and a standard deviation of
√
s21/n1 + s
2
2/n2,
where n1 and n2 are the numbers of cases in the two
datasets.
An in-house developed software (not published) run-
ning on a cluster of computers was used to process the
large numbers of SNP arrays. HapMap [27] data were
used as the unmatched references for inferring CNA
profiles.
Gene signature detection
A subtype signature is defined to be the set of genes
whose expressions are dys-regulated specifically in a sub-
type. To ensure this specificity, on top of statistical signif-
icance, we impose a fold change requirement.
First, given expressions {yj|j = 1, …, M} of a gene and
the corresponding trained subtype labels {Lj|Lj = 1, …,
K}, the purpose is to test if this gene is differentially
expressed in subtype k, as compared with all other
cases, regardless of their labels. This is a two-class fea-
ture selection problem, and can be efficiently handled
by LIMMA [28], with a correction of the multiple com-
parisons by the BH method [29].
Second, define the subtype-specific deviation:
k = min(|μk − min
=k
(μ)|, |μk − max
=k
(μ)|) (3)
and the non-specific deviation:
′k = |max
=k
(μ) − min
=k
(μ)| (4)
Here, µk and μ are the expected means of the corre-
sponding subtypes. A gene is said to be specific to subtype
k if μk > μ (or μk < μ) for all  = k, and the subtype-
specific fold change, FC (k) = k − ′k is greater than a
certain threshold (illustrated in Additional file 1 - Figure
S2). The set of genes that are determined to be both signif-
icantly expressed by LIMMA and specific to k shall be the
subtype signature of k, denoted as Sk.
Additional material
Additional file 1: Supplementary figures and tables.
Additional file 2: The converged signatures for the subtypes of the
three datasets.
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